Frontier mental health research: psychedelics & drug studies

Key findings

• Psychedelic‑assisted psychotherapy means a drug session plus hours of preparation and follow‑up therapy. ^{15096 15063 15053}
• MDMA‑assisted therapy has produced large benefits for people with PTSD in several controlled trials, including a larger recent trial, but regulatory approval is not settled. ^{15063 15078 15096}
• Psilocybin has shown promising help for major depression, treatment‑resistant depression, and anxiety in people with serious illness, but most trials are small or early‑stage. ^{15063 15055 15078}
• People who take psychedelics often report stronger feelings of connection to others and less of a separate self (called connectedness and ego‑dissolution), and these experiences are linked to better outcomes. ^{15062 15092 15052}
• Non‑drug factors — a person’s mindset, the physical and social setting, the therapist relationship, music, and careful integration afterward — strongly shape whether the treatment helps and whether people feel more connected. ^{15086 15092 15096}
• Naturalistic and survey studies report increases in social connectedness and personality changes like more agreeableness and less emotional reactivity after psychedelic experiences, but these studies cannot prove cause. ^{15052 15119}
• There are safety concerns: adolescents report more challenging sessions and higher rates of persistent visual symptoms, and some drugs can cause hallucinations that range from mild to severe and sometimes lead to lasting problems. ^{15119 15080}
• Biological studies suggest these drugs can make brain circuits more flexible and change social openness (for example, classic psychedelics act on serotonin receptors and MDMA boosts serotonin), but the exact healing mechanisms remain unclear. ^{15091 15086}
• The research field is growing again, but many trials are early and people from Indigenous and minority communities are often missing from studies and treatment planning. ^{15098 15094 15078}